Researchers from the Bellvitge Biomedical Research Institute (IDIBELL), the Sant Joan de Déu Research Institute (IRSJD), Sant Pau Research Institute (IIB Sant Pau) and the UB generated the first model of this disease that reproduce patients’ characteristics and response to treatment.
DEGS1 also appears as a main actor of mitochondrial function, which may have implications for the management of diseases caused by lipid imbalance.
This is a proposal coordinated by IDIBELL and financed by AGAUR in which 13 other institutions participate. XarSMART will offer projects access to experts in regulatory, eHealth, data science and precision medicine.
Bioinformaticians from the Bellvitge Biomedical Research Institute (IDIBELL) and geneticists from the Molecular Diagnostic Laboratory of the Catalan Institute of Oncology (ICO) joined forces to develop a program that facilitates genetic variants classification, as it collects and combines the available information to offer a first classification of the variants.
A bioinformatics program will accelerate the diagnosis of hereditary cancer Read More »
It is a project that delves into personalized medicine. This trial has been financed by the Carlos III Health Institute through R&D projects call in 2019, and by a grant from the Spanish Society of Cardiology.
The study compares the use of two drugs through what they have called a natural experiment, which opens the doors to a new research methodology to compare highly effective treatments, minimizing possible biases in the analysis of the different groups.
This course, the educational project has been implemented in a group of Baccalaureate from the Escola Pia of Igualada
VacunAcció once again challenges students to get vaccinated against misinformation Read More »
This is the largest and most complete study carried out on the subject, it has included more than 450,000 people from 9 European countries and has analyzed the relationship of diet with 25 different types of cancer. The work concludes that replacing 10% of the intake of processed products with others that are not reduces the risk of suffering any type of cancer.
Consumption of processed foods increases the risk of cancer Read More »
Between 2018 and 2019, the IDIBELL and Bellvitge University Hospital researcher Joan Sabater, in collaboration with the start-up LoopDx, developed SeptiLoop, a rapid sepsis diagnostic kit. The result of this project was patented and licensed to the company itself.
IDIBELL’s technology, licensed to LoopDx, starts a crowdequity campaign Read More »
Yesterday the award ceremony of the “la Caixa” Foundation scholarships was held. Dr. Albert Antolín, principal investigator of IDIBELL and ICO, received a Junior Leader grant to develop new strategies based on Big Data and artificial intelligence for the design of drugs against cancer that prevent drug resistance.
